SCHEMBL3595352

SCHEMBL3595352

Cc1ccc(-c2nnc(-c3cc(O)c(O)c([N+](=O)[O-])c3)o2)c(Br)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 2/20 0.43
POLB P06746 3/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HSP90AA1 P07900 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
CASP3 P42574 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
MAPT P10636 3/20 0.38
CTSB P07858 1/20 0.38
CTSH P09668 1/20 0.38
PIK3CD O00329 1/20 0.37
THRB P10828 1/20 0.37
GUSB P08236 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3581517 0.87 COMT (0.46) COMTPOLBMEN1KMT2AALDH1A1
SCHEMBL3592774 0.85 COMT (0.55) COMTPOLBLMNASMN1; SMN2RAB9A
SCHEMBL3582061 0.84 COMT (0.52) COMTPOLBLMNASMN1; SMN2RAB9A
SCHEMBL3597205 0.83 COMT (0.40) COMTMEN1KMT2AALDH1A1MAPT
SCHEMBL1448013 0.81 COMT (0.46) COMTPOLBMEN1KMT2AALDH1A1
SCHEMBL3581377 0.80 HSD11B1 (0.39) COMTMEN1KMT2AALDH1A1MAPT
SCHEMBL3592343 0.80 COMT (0.43) COMTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3588612 0.79 KDM4E (0.48) COMTPOLBMEN1KMT2AALDH1A1
SCHEMBL3586720 0.78 AR (0.38) COMTMEN1KMT2AALDH1A1MAPT
SCHEMBL3576676 0.78 COMT (0.48) COMTPOLBMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446012-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-09-20 US disclosed
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2014-01-23 US disclosed
US-8536203-B2 Pharmaceutical compounds BIAL-PORTELA & CA, S.A. (PT) 2013-09-17 US disclosed
EP-2617713-A1 New Pharmaceutical Compounds BIAL - Portela & Ca., S.A. (PT) 2013-07-24 EP disclosed
US-20100168113-A1 Pharmaceutical Compounds BIAL-PORTELA & CA., S.A. (PT) 2010-07-01 US disclosed
EP-2027091-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - Portela & Ca., S.A. (PT) 2009-02-25 EP disclosed
WO-2007117165-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168113-A1 Pharmaceutical Compounds PMP22, CNR2, OPRL1 COMT 10/4885POLB 3382/4885MEN1 3595/4885
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS PMP22, CNR2, OPRL1 COMT 10/4885POLB 3382/4885MEN1 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.